Perfil genómico completo para las necesidades de cada paciente

Alterations in targetable oncogenic

pathways in NSCLC

•

There are, on average, more than 300 non-synonymous mutations per

lung cancer but only a minority of these genes can promote

tumorigenesis.

•

Large scale genomic studies have recognized a variety of potential

therapeutic targets including

–

Establish (

EGFR, ALK, ROS

1, BRAF and PD-1/PD-L1)

–

Emerging (

MET, RET, NTRK

)

–

Elusive (

TP53, KRAS

)